Sun Pharmaceutical Industries Ltd

Sun Pharmaceutical Industries Ltd announced that CRISIL Ratings Limited ("CRISIL") has removed the ‘Rating Watch with Developing Implications’ status and reaffirmed the rating assigned to the Company's long-term bank facilities at ‘CRISIL AAA/Stable’ (Reaffirmed; Removed from ‘Rating Watch with Developing Implications’), referencing a prior communication dated May 7, 2026, which initially detailed CRISIL’s reaffirmation of the ‘CRISIL AAA’ rating with the aforementioned watch status following an announcement on April 27, 2026; no other rating agencies or instruments are mentioned in the communication.

Sun Pharmaceutical Industries Ltd share price ticked higher by 0.55% to Rs 2000.75 after the company's net profit grew slightly 6.87% to Rs 2910.8 crore, while revenue from operations improved marginally 4.28% to Rs 15183.55 crore in Q2FY26 over Q1FY26. The market capitalization of Pharmaceuticals industry group stocks on BSE stood at Rs 23.86 lakh crore, easing 5.84%. It has marginally improved by 2.27% over last one week and jumped by 15.01% in last one month while the market capitalization of Sun Pharmaceutical Industries Ltd has inched up 3.08% and 10.65% in the same period respectively. Profit before tax (PBT) of Sun Pharmaceutical Industries Ltd stood at Rs 4098.81 crore in Q2 FY26, expanding by 29.19% year-on-year, and jumping 15.42% quarter-on-quarter. EBITDA came in at Rs 3694 crore, declining 3.73% YoY and rising 5.67% sequentially. Total expenses saw a slight increase of 1.64% to Rs 11620.93 crore in Q2FY26 over Q2FY25. During the quarter, cost of materials consumed stood at Rs 2026.28 crore, slightly declining by 7.16% YoY, while employee benefits expense was at Rs 3227.23 crore, improving by 9.01% YoY. For the TTM ended FY26, revenue from operations rose 11.87% to Rs 58220.11 crore, while net profit saw a mild growth of 5.32% to Rs 11564.52 crore, compared to previous TTM. EBITDA witnessed a strong improvement of 1366811% to Rs 15759.68 crore, and PBT saw a minor gain of 9.94% to Rs 15118.88 crore compared to previous TTM. The company's consolidated net cash flow from operating activities stood at Rs 12419.18 crore in FY26, as against Rs 14072.09 crore in FY25. Sun Pharmaceutical Industries Ltd jumped 15.32% in last one year, significantly outperforming the benchmark BSE Sensex which has eased by 4.36% during the same period.

Net profit of Sun Pharmaceutical Industries rose 27.04% to Rs 2894.79 crore in the quarter ended June 2026 as against Rs 2278.63 crore during the previous quarter ended June 2025. Sales rose 10.14% to Rs 15183.55 crore in the quarter ended June 2026 as against Rs 13786.07 crore during the previous quarter ended June 2025. ParticularsQuarter EndedJun. 2026Jun. 2025% Var. Sales15183.5513786.07 10 OPM %29.1031.20 - PBDT5041.624691.32 7 PBT4302.903990.77 8 NP2894.792278.63 27 Powered by Capital Market - Live

Sun Pharmaceutical Industries Ltd gained for a fifth straight session today. The stock is quoting at Rs 2033.1, up 1.6% on the day as on 12:44 IST on the NSE. The benchmark NIFTY is up around 0.35% on the day, quoting at 24401.75. The Sensex is at 78214.53, up 0.37%. Sun Pharmaceutical Industries Ltd has gained around 8.94% in last one month. Meanwhile, Nifty Pharma index of which Sun Pharmaceutical Industries Ltd is a constituent, has gained around 5.81% in last one month and is currently quoting at 26346.05, up 1.14% on the day. The volume in the stock stood at 10.53 lakh shares today, compared to the daily average of 23.07 lakh shares in last one month. The benchmark August futures contract for the stock is quoting at Rs 2037, up 1.49% on the day. Sun Pharmaceutical Industries Ltd is up 24.75% in last one year as compared to a 0.67% slide in NIFTY and a 21.06% slide in the Nifty Pharma index.The PE of the stock is 163.06 based on TTM earnings ending March 26.

Sun Pharmaceutical Industries Limited announced it received approval from Brazil’s ANVISA to manufacture and market semaglutide injection in Brazil for the treatment of type 2 diabetes, planning a launch in the coming days in partnership with Hypera Pharma. The semaglutide injectable market in Brazil is approximately USD 413 million, according to IQVIA data from June 2026.

Sun Pharmaceutical Industries announced that the stockholders of Organon & Co. (Organon) have approved the proposals in connection with the previously announced merger transaction under which Organon is expected to become a wholly owned subsidiary of Sun Pharmaceutical Holdings USA, Inc., an indirect wholly owned subsidiary of Sun Pharma. The shareholder approval marks an important milestone towards completion of the proposed transaction. The acquisition remains subject to the satisfaction of the remaining customary closing conditions, including applicable regulatory approvals.

The key equity benchmarks witnessed strong gains in mid-morning trade supported by positive global cues after softer-than-expected U.S. inflation data eased concerns over further interest rate hikes by the Federal Reserve. Improved global risk sentiment and buying across frontline stocks lifted the domestic indices, with the Nifty trading above the 24,150 mark. Investors will continue to monitor developments in the US-Iran conflict, movements in crude oil prices, the ongoing Q1 earnings season, corporate business updates, and the progress of the southwest monsoon for further cues on market direction. Private bank shares recovered after falling in the previous trading session. At 11:25 IST, the barometer index, the S&P BSE Sensex advanced 479.41 points or 0.64% to 77,545.01. The Nifty 50 index added 133.95 points or 0.56% to 24,186. In the broader market, the BSE 150 MidCap Index jumped 0.62% and the BSE 250 SmallCap Index climbed 0.97%. The market breadth was strong. On the BSE, 2,495 shares rose and 1,346 shares fell. A total of 219 shares were unchanged. IPO Update: The initial public offer (IPO) of Alphine Texoworld received bids for 55.32 lakh shares as against 1.20 crore shares on offer, as per NSE data as of 11:21 hours on Wednesday (15 July 2026). The issue was subscribed 0.46 times. The issue opened for bidding on Tuesday (14 July 2026) and it will close on Thursday (16 July 2026). The price band of the IPO is fixed between Rs 100 to Rs 105 per share. The minimum order quantity is 142 equity shares. SBI Funds Management IPO received bids for 2.39 crore shares as against 14.51 crore shares on offer, according to stock exchange data at 11:21 IST on Wednesday (15 July 2026). The issue was subscribed 1.17 times. The issue opened for bidding on 14 July 2026 and it will close on 16 July 2026. The price band of the IPO is fixed between Rs 545 and 574 per share. An investor can bid for a minimum of 26 equity shares and multiples thereof. Buzzing Index: The Nifty Private Bank index advanced 1.01% to 28,198. The index declined 0.85% in the past trading session. Bandhan Bank (up 5.69%), IndusInd Bank (up 2.47%), Axis Bank (up 1.39%), ICICI Bank (up 1.13%) and HDFC Bank (up 0.93%), IDFC First Bank (up 0.71%), RBL Bank (up 0.57%), Kotak Mahindra Bank (up 0.51%), Yes Bank (up 0.51%) and Federal Bank (up 0.12%) advanced. Stocks in Spotlight: Sun Pharmaceutical Industries rose 0.89%. The company announced that it has received approval from the South African Health Products Regulatory Authority (SAHPRA) to manufacture and market a generic version of semaglutide injection in South Africa. Belrise Industries rose 2.45% after the company announced the launch of its qualified institutional placement (QIP) issue and fixed the floor price at Rs 230.79 per equity share. The floor price of Rs 230.79 per share is at a discount of 0.65% to the scrip's previous closing price of Rs 232.30 on the BSE. Global Markets: Asian markets advanced on Wednesday after a surprise slowdown in U.S. inflation scaled back market expectations for interest rate hikes, while oil took a breather as the U.S. scrapped a plan to levy shipping through the Strait of Hormuz. U.S. President ⁠Donald Trump reimposed a naval blockade of Iranian ports on Tuesday and threatened to attack power plants and bridges next week unless Iran resumes negotiations to end their conflict, though he scrapped a plan for a 20% fee on ⁠shipping through Hormuz. Meanwhile, China's economy in the second quarter expanded at its weakest pace since the fourth quarter of 2022. These figures reinforce calls for policy stimulus as an accelerating slide in investments deepened the strain on growth, while consumption stayed subdued. Gross domestic product growth came in at 4.3% in the April to June period, data from the National Statistics Bureau showed Wednesday, missing widely reported forecast for 4.5% growth, and slowing from 5% in the first quarter. That second-quarter growth came below Beijing's full-year growth target range of 4.5% to 5%, the least ambitious goal in decades, amid tensions with trade partners, including the U.S. and the European Union, and sluggish domestic demand. The S&P 500 and the Nasdaq advanced on Tuesday as solid big bank results and a cooler-than-expected inflation report boosted risk appetite amid rising Middle East tensions. The U.S. headline consumer price index fell 0.4% in June, its first decline since the COVID-19 pandemic, while annualised core inflation of 2.6% compared with widely reported expectations for 2.8%. The Labor Department's Consumer Price Index showed inflation cooled more than analysts expected in June, largely due to abating energy price pressures amid last month's signs of progress in U.S.-Iran peace negotiations.Powered by Capital Market - Live

The drug will be used for the treatment of adults with inadequately controlled type 2 diabetes mellitus as an adjunct to diet and exercise. Sun Pharma plans to launch the product in the market in the coming days. It will be available as a pre-filled, multi-dose injectable pen in two strengths'2 mg/1.5 mL and 4 mg/3 mL'allowing flexible, once-weekly dosing. 'South Africa is the second market after India where Sun Pharma has received approval for generic semaglutide. This reflects our ability to develop complex generic medicines that meet the stringent quality standards across different markets. We remain committed to improving access to generics and making evidence-based treatment options available to patients and healthcare professionals, said Aalok Shanghvi, chief operating officer, Sun Pharma. The company said that South Africa faces a growing burden of type 2 diabetes, driven in part by rapid urbanization and changing lifestyles. This rising prevalence places significant pressure on patients and the healthcare system. Improving access to effective therapies is therefore an important component of addressing this national health challenge. Sun Pharmaceutical Industries is engaged in the business of manufacturing, developing and marketing a wide range of branded and generic formulations and active pharmaceutical ingredients (APIs). The company and its subsidiaries has various manufacturing facilities spread across the world, with trading and other incidental and related activities extending to the global market. It is the largest pharmaceutical company in India. The company had reported a 26.24% rise in consolidated net profit to Rs 2,714.03 crore in Q4 FY26 as against Rs 2,149.88 crore posted in the same period year ago. Total revenue from operations increased 12.75% YoY to Rs 14,611.79 crore in the quarter ended 31 March 2026. The scrip rose 0.46% to currently trade at Rs 1,949 on the BSE. Powered by Capital Market - Live

Sun Pharmaceutical Industries has received approval from the South African Health Products Regulatory Authority (SAHPRA) to manufacture and market a generic version of semaglutide injection in South Africa for the treatment of adults with inadequately controlled type 2 diabetes mellitus as an adjunct to diet and exercise. Sun Pharma plans to launch the product in the market in the coming days. It will be available as a pre-filled, multi-dose injectable pen in two strengths (2 mg/1.5 mL and 4 mg/3 mL) that allow flexible, once-weekly dosing. 'South Africa is the second market after India where Sun Pharma has received approval for generic semaglutide. This reflects our ability to develop complex generic medicines that meet the stringent quality standards across different markets. We remain committed to improving access to generics and making evidence-based treatment options available to patients and healthcare professionals, said Aalok Shanghvi, Chief Operating Officer, Sun Pharma.

Sun Pharmaceuticals Industries will hold a meeting of the Board of Directors of the Company on 31 July 2026.